Former Director Sanjay Bansal has sold 40,000 equity shares of Shivalik Rasayan Limited through the open market, reducing his stake to 1.01%. The transaction, valued at ₹1.02 crore, was executed on the National Stock Exchange (NSE) on June 2, 2026. The company disclosed this development to the exchanges on June 4, 2026, to comply with insider trading regulations.

The intimation was submitted to BSE Limited and the National Stock Exchange of India Ltd in Form-D. This disclosure was made pursuant to Regulation 7(3) read with Regulation 6(2) of the SEBI (Prohibition of Insider Trading) Regulations, 2015. The filing identified Mr. Bansal as a former Director and a connected person.

Transaction Details

The following table outlines the key details of the share sale:

The company confirmed that the intimation was in compliance with the regulatory framework. The disclosure was signed by Parul Choudhary, Company Secretary & Compliance Officer for Shivalik Rasayan Limited.

Shivalik Rasayan Limited reported a 12% decline in consolidated net profit to ₹1,796.88 lakh for the financial year ended March 31, 2026, compared to ₹2,042.26 lakh in the previous year. Revenue from operations for the consolidated entity increased 18% to ₹36,800.32 lakh from ₹31,177.31 lakh in FY25. The board approved the audited financial results and recommended a final dividend of 50 paise per equity share, subject to shareholder approval.

For the quarter ended March 31, 2026, the company reported a consolidated net profit of ₹717.32 lakh, a rise from ₹519.06 lakh in the corresponding quarter of the previous year. Total revenue for the quarter stood at ₹10,473.21 lakh. The statutory auditors, M/s Rahul Chaudhary & Associates, issued an unmodified opinion on the financial results.

Financial Performance

The standalone net profit for FY26 stood at ₹817.25 lakh, a decrease from ₹1,386.68 lakh in the previous year. Standalone revenue from operations for the year was ₹17,023.35 lakh, up from ₹14,922.59 lakh in FY25. The company operates across three business segments: Agro Chemical, Pharma API, and Pharma Formulations. The consolidated results include the financials of its associate, Medicamen Biotech Limited.

Board Decisions

The board approved the appointment of M/s Arun Agarwal & Co. as the Internal Auditor for FY27, following the resignation of M/s Amar Sharma & Co. Cheena & Associates were appointed as the Cost Auditor for FY27. The board accepted the resignation of Mr. Sanjay Bansal as a Non-Executive Director and reconstituted the Audit Committee, Stakeholders Relationship Committee, Nomination and Remuneration Committee, and Risk Management Committee effective May 27, 2026.